Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AN2 Therapeutics, Inc. (Nasdaq: ANTX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. AN2 describes itself as a clinical-stage biopharmaceutical company developing novel small molecule therapeutics from its boron chemistry platform, with programs in Chagas disease, melioidosis, NTM lung disease caused by Mycobacterium abscessus, and oncology targets.
Periodic and current reports such as Forms 10-K, 10-Q, and 8-K provide detail on AN2’s research and development expenses, cash position, and progress across its pipeline. For example, recent Form 8-K filings reference press releases reporting quarterly financial results, including operating expenses and net loss, and describe how the company is advancing clinical trials and collaborations. These documents help investors understand how AN2 funds and prioritizes its infectious disease and oncology programs.
Regulatory filings can also disclose capital structure changes. A Form 8-K describes AN2’s issuance of pre-funded warrants in exchange for common stock to an institutional investor, including key terms such as exercise price and beneficial ownership limitations. Such filings give insight into how the company structures financing while managing ownership thresholds.
On this page, users can access AN2’s annual reports (Form 10-K) and quarterly reports (Form 10-Q) once filed, along with current reports (Form 8-K) that cover material events, collaborations, and financial updates. AI-powered summaries on Stock Titan are designed to highlight the main points in lengthy filings, helping readers quickly identify items related to clinical development, cash runway, or capital transactions without reading every line.
Investors interested in AN2’s ongoing work in Chagas disease, melioidosis, NTM lung disease, tuberculosis collaborations, and oncology targets can use the filings page to review the company’s official disclosures and track how its boron chemistry platform is reflected in its regulatory reporting.
Eizen Joshua M reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics officer Joshua M. Eizen reported new equity awards. He was granted a stock option covering 100,000 shares, which vests in equal monthly installments over four years from January 1, 2026, subject to continued service. He also received 50,000 restricted stock units that vest 25% annually over four years from January 1, 2026, on the same service condition. Following these awards, he directly owns 207,499 shares of common stock, which includes prior RSU grants and a 5,000-share purchase under the 2022 Employee Stock Purchase Plan on March 31, 2025.
Day Lucy reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics, Inc. Chief Financial Officer Lucy Day reported equity awards consisting of a stock option for 77,000 shares and a grant of 38,000 shares of common stock on February 20, 2026. The common stock amount represents restricted stock units that vest 1/4 annually over four years from January 1, 2026, subject to continued service. The option vests 1/48 monthly over four years from the same date on a continued-service basis. Her common stock holdings total 118,363 shares, reflecting prior RSU grants of 27,500 and 46,500 units with annual vesting from January 1, 2024 and January 1, 2025, and a 5,000-share purchase under the 2022 Employee Stock Purchase Plan on March 31, 2025.
Williams Sarah Joanne reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics Principal Accounting Officer Sarah Joanne Williams received a grant of 48,375 shares of common stock in the form of restricted stock units. The RSUs vest over four years, with one quarter of the shares vesting annually from January 1, 2026, contingent on her continued service.
After this award, Williams directly holds 67,175 shares, including prior RSU grants described in the footnotes. Those earlier RSUs vest on separate annual and quarterly schedules, also conditioned on her remaining in service with the company.
AN2 Therapeutics, Inc. director and Chief Executive Officer Eric Easom reported new equity awards. He received a stock option for 224,500 shares at an exercise price of $0.0000 per share and a grant of 112,250 shares of Common Stock on February 20, 2026.
The 112,250-share grant represents restricted stock units that vest in 25% increments annually over four years from January 1, 2026, subject to continuous service. The option vests 1/48 of the shares monthly over four years from January 1, 2026. Easom also reports indirect ownership of Common Stock through the Easom Living Trust and two irrevocable trusts.
AN2 Therapeutics Chief Development Officer Sanjay Chanda reported new equity awards. On February 20, 2026, he received a grant of stock options for 77,000 shares at an exercise price of $0.00 per share, vesting monthly over four years from January 1, 2026.
He also acquired 38,000 shares of common stock as restricted stock units that vest annually in four installments from January 1, 2026, subject to continued service. Following these awards, he directly holds 77,000 options and 118,823 common shares, which include previously granted RSUs and shares purchased under the 2022 Employee Stock Purchase Plan.
Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Marks Gilbert Lynn reported receiving a grant of stock options covering 20,400 shares. The options are scheduled to vest on February 20, 2027, provided he continues to provide service to the company through that date.
Readnour Robin Shane reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Robin Shane Readnour reported an equity award in the form of stock options for 20,400 shares. The options were granted as a compensation award and will vest on February 20, 2027, provided Readnour continues to provide service to the company through that date.
AN2 Therapeutics, Inc. director Stephanie Wong received a grant of stock options covering 20,400 shares on February 20, 2026. The options were granted at an exercise price of $0.00 per share and will vest on February 20, 2027, provided she continues to serve through that date.
AN2 Therapeutics director Patricia A. Martin received a stock option grant for 20,400 shares of common stock of AN2 Therapeutics, Inc. The option was awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
The option shares will vest on February 20, 2027, provided Martin continues to provide service to the company through that date. Following this award, she holds 20,400 option shares directly, aligning her compensation more closely with the company’s future share performance.
AN2 Therapeutics, Inc. director Melvin K. Spigelman reported receiving a grant of stock options covering 20,400 shares of the company’s stock. The award was recorded as an acquisition of derivative securities held directly by him. According to the filing, these option shares will vest on February 20, 2027, provided he continues to provide service to the company through that date.